IRLAB Therapeutics AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRLAB-A.ST research report →
Companywww.irlab.se
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases.
- CEO
- Kristina Torfgard
- IPO
- 2017
- Employees
- 31
- HQ
- Gothenburg, SE
Price Chart
Valuation
- Market Cap
- $107.09M
- P/E
- -1.54
- P/S
- 1.16
- P/B
- 2.59
- EV/EBITDA
- -1.71
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -42.97%
- Op Margin
- -59.52%
- Net Margin
- -72.37%
- ROE
- -275.71%
- ROIC
- -82.23%
Growth & Income
- Revenue
- $57.46M · -39.28%
- Net Income
- $-110,010,000 · -32.34%
- EPS
- $-1.64 · -2.50%
- Op Income
- $-92,348,000
- FCF YoY
- 16.06%
Performance & Tape
- 52W High
- $7.88
- 52W Low
- $1.17
- 50D MA
- $1.45
- 200D MA
- $2.09
- Beta
- 0.53
- Avg Volume
- 212.77K
Get TickerSpark's AI analysis on IRLAB-A.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IRLAB-A.ST Coverage
We haven't published any research on IRLAB-A.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IRLAB-A.ST Report →